Short Summary
The PTAB instituted an inter partes review of Inari Medical’s 11,554,005 patent covering intravascular embolism treatment devices after finding Imperative Care’s likelihood of success on at least one claim. The decision centers on claim constructions of the “filament” element and obviousness over multiple prior‑art references.
Detailed Summary
In a Decision Granting Institution of Inter Partes Review, the Patent Trial and Appeal Board concluded that Imperative Care, Inc. has shown a reasonable likelihood of prevailing on at least one of the fifteen claims of Inari Medical’s U.S. Patent No. 11,554,005 B2, which claims a vacuum aspiration system with a hemostasis valve. The Board examined four statutory grounds, all under 35 U.S.C. § 103, relying on prior‑art references Garrison, Schaffer, Hartley, and Eller. A key dispute involved the term “filament,” where the petitioner defined it broadly, the patent owner emphasized flexibility, and the Board declined to limit the term for claim 1 while requiring flexibility for claim 10. Consequently, the IPR was instituted on all challenged claims, setting the stage for a full trial on obviousness and claim construction issues.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Imperative Care, Inc. vs Inari Medical, Inc. et al. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Samsung Electronics Co., Ltd. et al.vsEyesMatch Ltd.
EyesMatch Ltd. seeks Director review of a PTAB Final Written Decision that found all claims of its imaging patent unpatentable. The Patent Owner contends Samsung and Google introduced new arguments and prior art in a reply, violating IPR rules and inconsistent claim constructions. The request asks the Director to reverse the decision.
Champion Laboratories, Inc. et al.vsHENGST SE
The PTAB decided to institute the IPR challenge against HENGST SE's patent, finding that Petitioner met the reasonable likelihood standard for claim 1 despite parallel district court litigation. The Board determined that Fintiv factors outweighed those favoring discretionary denial.
Micron Technology, Inc. et al.vsYangtze Memory Technologies Company, Ltd.
The PTAB found claims 1-7 and 18 unpatentable over the prior art reference Toyama under 35 U.S.C. § 103. The Board issued a Final Written Decision after addressing several key claim construction disputes regarding isolation regions, dielectric structures, and local contacts.
Texas Instruments IncorporatedvsParkerVision, Inc.
Texas Instruments (TI) successfully secured the institution of its IPR against ParkerVision, Inc., establishing a reasonable likelihood of prevailing on obviousness grounds. The Board found that TI's evidence was sufficient at this stage to overcome arguments regarding inherency and simulation data reliability.
US Conec Ltd.vsSenko Advanced Components, Inc.
US Conec Ltd. successfully secured institution of IPR against Senko Advanced Components, Inc.'s optical connector patent (11307369), challenging 22 claims based on obviousness and anticipation.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.